The technology used to build Chiromics’ libraries, employs a chemical synthesis technique referred to as ‘cascade catalysis.’ According to the company, cascade catalysis helps create a diverse collection
MM-151 is an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of the epidermal growth factor receptor (EGFR).
As per the collaboration, Camurus has granted Novartis an option to license the FluidCrystal Injection depot technology to develop, manufacture and commercialize Camurus’ octreotide product CAM2029 and related
The new solution, QTinno is intended to be used for an upcoming Thorough QT trial. According to the company, QTinno 3-D ECG software technology is a novel, fully
The manufacturing plant is expected to produce critical care injectable and oncological drugs and begin operations in 2015. The 210 acres facility that previously belonged to Pfizer will
The test is intended to identify non-small cell lung cancer (NSCLC) patients with anaplastic lymphoma receptor tyrosinekinase (ALK) gene rearrangements who may benefit from Pfizer’s XalkorI (crizotinib). The
In March 2011, Epizyme and Eisai signed a global strategic alliance to discover, develop and commercialize therapeutics targeting EZH2, an epigenetic enzyme as a treatment for lymphoma and
The rhFSH analog is developed through Trophogen’s proprietary superagonist hormone technology platform originally licensed from the National Institutes of Health. The contract manufacturing deal includes the technology transfer
Cubist and Hydra have recently identified and completed preclinical testing on a novel small molecule antagonist of the human TRPA1 channel, CB-625 (CB-189,625), and filed for regulatory approval
The certificate was granted following inspection of the facility in November 2011. Ablynx’s GMP unit will now perform release-testing on Drug Substance and Drug Product batches besides independently
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.